Laparoscopic Roux-en-Y Gastric Bypass Effectively Cures Co-Morbid Diseases Associated with Morbid Obesity
Abstracts
|
Background: A significant number of patients with morbid obesity have associated co-morbid diseases. The aim of this study is to determine the therapeutic effect of laparoscopic Roux-en-Y gastric bypass (LRYGB) on these co-morbid diseases. Methods: We reviewed our experience with 107 consecutive patients undergoing LRYGB for morbid obesity at one institution by one surgeon. Data regarding co-morbid diseases and medications were collected from a prospective database. Results: The mean age is 44 years and the mean body mass index 48.5 Kg/m2. The mean follow-up is 5.1 months. 80 patients (70%) were on various medications before surgery for co-morbidities associated with morbid obesity. A substantial number of patients who remained on medical treatment after surgery decreased the number or the dose of the pre-operative medications. Conclusion: LRYGB completely cures co-morbid diseases in a significant number of morbidly obese patients. |
